Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:investor
|
| gptkbp:businessModel |
private equity
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:director |
gptkb:John_Diekman
gptkb:David_Beier Erik Harris Fred Craves |
| gptkbp:focusesOn |
gptkb:biotechnology
life sciences healthcare investments |
| gptkbp:foundedIn |
1997
|
| gptkbp:headquartersLocation |
gptkb:San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Bay City Capital
|
| gptkbp:investedIn |
gptkb:Cytokinetics
gptkb:Ambrx gptkb:Achaogen gptkb:Pharmacyclics gptkb:Portola_Pharmaceuticals gptkb:Titan_Pharmaceuticals MAP Pharmaceuticals NuGEN Technologies |
| gptkbp:numberOfEmployees |
11-50
|
| gptkbp:website |
https://www.baycitycapital.com/
|
| gptkbp:bfsParent |
gptkb:Pritzker_Organization
|
| gptkbp:bfsLayer |
8
|